Integrating common and rare genetic variation in autism spectrum disorder
Integrating common and rare genetic variation in autism spectrum disorder
批准号:
10382806
负责人:
Daniel Weiner
金额:
$3.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-01 至 2025-01-31
关键词:
AccountingAdultAffectBiologicalBiological ProcessBiological Response Modifier TherapyBiologyCell NucleusCodeCommunicationData SetDiseaseDoctor of PhilosophyEnvironmentFamilyFellowshipFoundationsFunctional disorderFundingGene ExpressionGene Expression RegulationGene TargetingGenesGeneticGenetic VariationGenomeGenomic SegmentGoalsHeritabilityImpairmentInstitutesMediatingMediationMentorshipMethodsModelingNeuronsPathway interactionsPharmacological TreatmentPhysiciansPopulationResearch TrainingResourcesRiskRisk FactorsScientistSymptomsTest ResultTestingTissuesTrainingUncertaintyUnited States National Institutes of HealthUntranslated RNAVariantWorkautism spectrum disorderbrain tissuecareercausal variantcell typecohortexome sequencinggenetic risk factorgenome wide association studygenome-wideimprovedneuropsychiatrynovelprogramsrare variantrelating to nervous systemrepetitive behaviorsocial communicationstatisticstherapeutic developmenttranscriptomicstransmission process
中文摘要
项目摘要
自闭症谱系障碍(ASD)很常见,通常是致残的。目前,还没有任何药理作用
对其核心症状的治疗:社交沟通障碍和限制/重复行为。这个
ASD的高遗传率表明,了解其遗传风险因素将有助于定义ASD
病理生理学和促进治疗的发展。ASD在人群中的最大遗传风险因素
水平是常见的多基因变异,数千个小效SNPs的加性影响用
GWARD。然而,对多基因风险的解释是具有挑战性的:大多数与疾病相关的SNPs是非
编码时,它们的靶基因(S)的身份是不确定的,它们对基因表达的影响往往是
未知。因此,受asd常见多基因风险影响的基因和生物通路仍然很差。
已定义。相比之下,最近对罕见编码变异的研究发现>;70基因与自闭症(ASD)有关
基因“),它们共同强调了与ASD相关的生物过程。定义多基因风险的生物学
对于ASD来说,了解多基因风险与基因汇聚的程度是至关重要的。
以及通过罕见的变异研究确定的途径。我们建议应用三种新的统计和
功能性方法(A)解释ASD的常见多基因风险和(B)评估趋同性
ASD和ASD基因共同的多基因风险。在目标1中,我们引入了分层多基因
传递不平衡检验(S-pTDT),用于检测由小基因引起的多基因风险
基因组的区域。我们将使用S-pTDT来量化ASD的多基因风险浓度在
围绕着自闭症基因。在目标2中,我们介绍了一种理解多基因风险如何影响基因的方法。
表达,利用成人人脑组织的大型单核转录数据集。我们将使用
这一方法检验了ASD的多基因风险降低ASD基因表达的假设,并
在基因组区域提名ASD多基因相关性较高的候选致病基因。在《目标3》中,
我们引入了抽象中介模型(AMM),它量化了共同变量的比例
遗传力由基因集介导,同时解释了非编码SNPs基因靶标的不确定性。我们
将应用AMM来估计ASD的多基因风险在多大程度上是由ASD基因和其他
ASD相关基因集。这些目标将提高我们对ASD基因基础的理解,
加强生物学和治疗假说,并产生适用于其他神经精神病学的方法
条件。最后,研究性培训将在哈佛/麻省理工学院医学博士学位的激励环境中进行
麻省理工学院和哈佛大学的项目和广泛的研究所。在他的赞助商的指导下,联谊会将
完成五个培训目标,这些目标将为NIH资助的内科科学家的职业生涯奠定基础。
英文摘要
Project Summary
Autism spectrum disorder (ASD) is common and often disabling. Currently, there are no pharmacologic
treatments for its core symptoms: impairment in social communication and restricted/repetitive behavior. The
high heritability of ASD suggests that understanding its genetic risk factors will help define ASD
pathophysiology and facilitate therapeutic development. The largest genetic risk factor for ASD on a population
level is common polygenic variation, the additive influence of thousands of small effect SNPs estimated with
GWAS. However, interpretation of polygenic risk is challenging: most disease-associated SNPs are non-
coding, the identity of their target gene(s) is uncertain, and their influence on gene expression is often
unknown. Thus, the genes and biological pathways affected by common polygenic risk for ASD remain poorly
defined. In contrast, recent studies of rare coding variation have associated >70 genes with ASD (“ASD
Genes”), which collectively highlight ASD-relevant biological processes. To define the biology of polygenic risk
for ASD, it is critically important to understand the degree to which polygenic risk converges with the genes
and pathways identified through rare variant studies. We propose to apply three novel statistical and
functional approaches to (a) interpret common polygenic risk for ASD and (b) assess the convergence
of common polygenic risk for ASD and ASD Genes. In Aim 1, we introduce the Stratified-polygenic
Transmission Disequilibrium Test (S-pTDT), which is powered to examine polygenic risk arising from small
regions of the genome. We will use S-pTDT to quantify the concentration of polygenic risk for ASD in and
around ASD Genes. In Aim 2, we introduce an approach to understand how polygenic risk influences gene
expression, leveraging a large single-nucleus transcriptomic dataset of adult human brain tissue. We will use
this approach to test the hypothesis that polygenic risk for ASD decreases expression of ASD Genes, and to
nominate candidate causal genes in genomic regions with heightened polygenic relevance in ASD. In Aim 3,
we introduce the Abstract Mediation Model (AMM), which quantifies the proportion of common-variant
heritability mediated by gene sets while accounting for uncertainty in the gene targets of non-coding SNPs. We
will apply AMM to estimate the extent to which polygenic risk for ASD is mediated by ASD Genes and other
ASD-relevant gene sets. These Aims will improve our understanding of the genetic underpinnings of ASD,
strengthen biological and therapeutic hypotheses, and generate methods applicable to other neuropsychiatric
conditions. Finally, this research training will occur in the stimulating environment of the Harvard/MIT MD/PhD
Program and Broad Institute of MIT and Harvard. Under the guidance of his sponsors, the fellowship PI will
complete five training goals that will create the foundation for a career as an NIH-funded physician-scientist.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrating common and rare genetic variation in autism spectrum disorder
-
批准号:10548147
-
项目类别:
-
资助金额:$4.03万
-
财政年份:2022
-
负责人:Daniel Weiner
-
依托单位:
海外基金